Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology

Brain Research Reviews

Volumn 58, Issue 2, 2008, Pages 415-452

  Fuxe, K ^a   Marcellino, D ^a   Rivera, A ^b   Diaz Cabiale, Z ^b   Filip, M ^c   Gago, B ^b   Roberts, D C S ^d   Langel, U ^e   Genedani, S ^h   Ferraro, L ^f   de la Calle, A ^b   Narvaez, J ^b   Tanganelli, S ^f   Woods, A ^g   Agnati, L F ^h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e STOCKHOLM UNIVERSITY   (Sweden)

^f UNIVERSITY OF FERRARA   (Italy)

^g NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

5 HT1A receptor; Adenosine receptor; CB1 receptor; Depression; Dopamine receptor; Drug addiction; Galanin receptor; Heteromerization; mGluR5; Parkinson's disease; Schizophrenia; Striatum; Treatment strategy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; BENZAMIDE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; GALANIN; GALANIN RECEPTOR ANTAGONIST; HALOPERIDOL; LEVODOPA; MEMBRANE RECEPTOR; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; QUINPIROLE; RECEPTOR MOSAIC; RECEPTOR PROTEIN; REMOXIPRIDE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; BINDING SITE; CATALEPSY; COCAINE DEPENDENCE; DEPRESSION; DIENCEPHALON; DRUG POTENTIATION; DRUG TARGETING; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PSYCHOPHARMACOLOGY; RAPHE NUCLEUS; RECEPTOR POTENTIAL; REVIEW; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TELENCEPHALON;

ANIMALS; CELL COMMUNICATION; HUMANS; NEURONS; PSYCHOPHARMACOLOGY; RECEPTORS, CELL SURFACE;

EID: 46249098051     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2007.11.007     Document Type: Review

References (283)

1. Agnati L.F., and Fuxe K. Volume transmission as a key feature of information handling in the central nervous system possible new interpretative value of the Turing's B-type machine. Prog. Brain Res. 125 (2000) 3-19
2. Agnati L.F., Fuxe K., Zini I., Lenzi P., and Hokfelt T. Aspects on receptor regulation and isoreceptor identification. Med. Biol. 58 (1980) 182-187
3. Agnati L.F., Fuxe K., Zoli M., Rondanini C., and Ogren S.O. New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med. Biol. 60 (1982) 183-190
4. Agnati L.F., Fuxe K., Zoli M., Ozini I., Toffano G., and Ferraguti F. A correlation analysis of the regional distribution of central enkephalin and beta-endorphin immunoreactive terminals and of opiate receptors in adult and old male rats. Evidence for the existence of two main types of communication in the central nervous system: the volume transmission and the wiring transmission. Acta Physiol. Scand. 128 (1986) 201-207
5. Agnati L.F., Fuxe K., Zoli M., Ferraguti F., Benfenati F., Ouimet C.C., Walaas S.I., Hemmings Jr. H.C., Goldstein M., and Greengard P. Morphometrical evidence for a complex organization of tyrosine hydroxylase-, enkephalin- and DARPP-32-like immunoreactive patches and their codistribution at three rostrocaudal levels in the rat neostriatum. Neuroscience 27 (1988) 785-797
6. Agnati L.F., Ferre S., Cortelli P., and Fuxe K. A brief appraisal on some aspects of the receptor-receptor interaction. Neurochem. Int. 27 (1995) 139-146
7. Agnati L., Santarossa L., Benfenati F., Ferri M., Morpurgo A., Apolloni B., and Fuxe K. Molecular basis of learning and memory: modelling based on receptor mosaics. In: Apolloni B., and Kurfes F. (Eds). From Synapses to Rules (2002), Kluwer Academic/Plenum Publishers, New York 165-196
8. Agnati L.F., Ferre S., Lluis C., Franco R., and Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55 (2003) 509-550
9. Agnati L.F., Franzen O., Ferre S., Leo G., Franco R., and Fuxe K. Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. J. Neural Transm., Suppl. (2003) 1-28
10. Agnati L.F., Fuxe K., and Ferre S. How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends Biochem Sci. 30 (2005) 188-193
11. Agnati L.F., Tarakanov A.O., Ferre S., Fuxe K., and Guidolin D. Receptor-receptor interactions, receptor mosaics, and basic principles of molecular network organization: possible implications for drug development. J. Mol. Neurosci. 26 (2005) 193-208
12. Agnati L.F., Guidolin D., Leo G., and Fuxe K. A boolean network modelling of receptor mosaics relevance of topology and cooperativity. J. Neural Transm. 114 (2007) 77-92
13. Agnati L.F., Guidolin D., Genedani S., Arhem P., Fomi A., Andreoli N., and Fuxe K. Role of cooperativity in protein folding and protein mosaic assemblage. Relevance for protein conformational diseases. Curr. Protein Pept. Sci. 8 (2007) 460-470
14. Anden N.E., Dahlstrom A., Fuxe K., and Larsson K. Functional role of the nigro-neostriatal dopamine neurons. Acta Pharmacol. Toxicol. (Copenh) 24 (1966) 263-274
15. Anden N.E., Butcher S.G., Corrodi H., Fuxe K., and Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur. J. Pharmacol. 11 (1970) 303-314
16. Andersen M.B., Fuxe K., Werge T., and Gerlach J. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav. Pharmacol. 13 (2002) 639-644
17. Andersson M., Terasmaa A., Fuxe K., and Stromberg I. Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia. J. Neurosci. Res. 82 (2005) 264-272
18. Andersson M., Usiello A., Borgkvist A., Pozzi L., Dominguez C., Fienberg A.A., Svenningsson P., Fredholm B.B., Borrelli E., Greengard P., and Fisone G. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J. Neurosci. 25 (2005) 8432-8438
19. 2 receptor interactions in a model of Parkinson's disease. Relevance for l-dopa induced dyskinesias. J. Neurol. Sci. 248 (2006) 16-22
20. Arnold J.C. The role of endocannabinoid transmission in cocaine addiction. Pharmacol. Biochem. Behav. 81 (2005) 396-406
21. Arnold J.C., Topple A.N., Hunt G.E., and McGregor I.S. Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. Eur. J. Pharmacol. 354 (1998) 9-16
22. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
23. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
24. Barr A.M., Kinney J.W., Hill M.N., Lu X., Biros S., Rebek Jr. J., and Bartfai T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci. Lett. 405 (2006) 111-115
25. Bartfai T., Lu X., Badie-Mahdavi H., Barr A.M., Mazarati A., Hua X.Y., Yaksh T., Haberhauer G., Ceide S.C., Trembleau L., Somogyi L., Krock L., and Rebek Jr. J. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10470-10475
26. Bellido I., Diaz-Cabiale Z., Jimenez-Vasquez P.A., Andbjer B., Mathe A.A., and Fuxe K. Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci. Lett. 317 (2002) 101-105
27. Beltramo M., de Fonseca F.R., Navarro M., Calignano A., Gorriti M.A., Grammatikopoulos G., Sadile A.G., Giuffrida A., and Piomelli D. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J. Neurosci. 20 (2000) 3401-3407
28. 3 receptors for the activation of extracellular signal-regulated kinase. J. Biol. Chem. 279 (2004) 28304-28314
29. 3 receptor function. Nat. Med. 9 (2003) 762-767
30. Bockaert J., Marin P., Dumuis A., and Fagni L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett. 546 (2003) 65-72
31. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3363-3367
32. Borgkvist A., Marcellino D., Fuxe K., Greengard P., and Fisone G. Regulation of DARPP-32 phosphorylation by Delta(9)-tetrahydrocannabinol. Neuropharmacology (2007)
33. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev., Neurosci. 2 (2001) 274-286
34. Brami-Cherrier K., Valjent E., Garcia M., Pages C., Hipskind R.A., and Caboche J. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J. Neurosci. 22 (2002) 8911-8921
35. Branchek T., Smith K.E., and Walker M.W. Molecular biology and pharmacology of galanin receptors. Ann. N. Y. Acad. Sci. 863 (1998) 94-107
36. Bulenger S., Marullo S., and Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26 (2005) 131-137
37. Caberlotto L., Jimenez P., Overstreet D.H., Hurd Y.L., Mathe A.A., and Fuxe K. Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. Neurosci. Lett. 265 (1999) 191-194
38. Caberlotto L., Fuxe K., Overstreet D.H., Gerrard P., and Hurd Y.L. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res. Mol. Brain Res. 59 (1998) 58-65
39. Caille S., and Parsons L.H. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 31 (2006) 804-813
40. Caille S., Alvarez-Jaimes L., Polis I., Stouffer D.G., and Parsons L.H. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J. Neurosci. 27 (2007) 3695-3702
41. Caine S.B., Negus S.S., Mello N.K., and Bergman J. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J. Pharmacol. Exp. Ther. 291 (1999) 353-360
42. 2 agonist in the treatment of parkinsonism. Mov. Disord. 13 (1998) 768-774
43. Calon F., Dridi M., Hornykiewicz O., Bedard P.J., Rajput A.H., and Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 (2004) 1075-1084
44. Canales J.J. Stimulant-induced adaptations in neostriatal matrix and striosome systems: transiting from instrumental responding to habitual behavior in drug addiction. Neurobiol. Learn. Mem. 83 (2005) 93-103
45. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278 (2003) 46741-46749
46. Carlezon Jr. W.A., Thome J., Olson V.G., Lane-Ladd S.B., Brodkin E.S., Hiroi N., Duman R.S., Neve R.L., and Nestler E.J. Regulation of cocaine reward by CREB. Science 282 (1998) 2272-2275
47. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh) 20 (1963) 140-144
48. Carlsson A., Corrodi H., Fuxe K., and Hokfelt T. Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. Eur. J. Pharmacol. 5 (1969) 367-373
49. Carlsson A., Fuxe K., and Ungerstedt U. The effect of imipramine on central 5-hydroxytryptamine neurons. J. Pharm. Pharmacol. 20 (1968) 150-151
50. Carlsson A., Fuxe K., Hamberger B., and Lindqvist M. Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol. Scand. 67 (1966) 481-497
51. Carriba P., Ortiz O., Patkar K., Justinova Z., Stroik J., Themann A., Muller C., Woods A.S., Hope B.T., Ciruela F., Casado V., Canela E.I., Lluis C., Goldberg S.R., Moratalla R., Franco R., and Ferre S. Striatal adenosine a(2a) and cannabinoid CB(1) receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32 (2007) 2249-2259
52. 2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic transmission. Neuropsychopharmacology 29 (2004) 1488-1497
53. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev., Neurosci. 4 (2003) 299-309
54. Chase T.N. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat. Disord. 10 (2004) 305-313
55. 2A antagonist KW6002 from animal models to Parkinsonian patients. Neurology 61 (2003) S107-S111
56. Chen J.P., Paredes W., Lowinson J.H., and Gardner E.L. Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci. Lett. 129 (1991) 136-180
57. Chiang M.C., Lee Y.C., Huang C.L., and Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 280 (2005) 14331-14340
58. 2 receptors. Anal. Chem. 76 (2004) 5354-5363
59. 2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29 (2004) 1451-1461
60. Conn P.J., Battaglia G., Marino M.J., and Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev., Neurosci. 6 (2005) 787-798
61. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., and Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57 (2005) 594-608
62. Dahlstroem A., and Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand., Suppl. 232 (1964) 1-55 SUPPL
63. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L.J., and Schoffelmeer A.N. A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med. 7 (2001) 1151-1154
64. Dean B., Sundram S., Bradbury R., Scarr E., and Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103 (2001) 9-15
65. Diaz-Cabiale Z., Narvaez J.A., Finnman U.B., Bellido I., Ogren S.O., and Fuxe K. Galanin-(1-16) modulates 5-HT1A receptors in the ventral limbic cortex of the rat. Neuroreport 11 (2000) 515-519
66. Diaz-Cabiale Z., Narvaez J.A., Yanaihara N., Gonzalez-Baron S., and Fuxe K. Galanin/alpha2-receptor interactions in central cardiovascular control. Neuropharmacology 39 (2000) 1377-1385
67. Diaz-Cabiale Z., Petersson M., Narvaez J.A., Uvnas-Moberg K., and Fuxe K. Systemic oxytocin treatment modulates alpha 2-adrenoceptors in telencephalic and diencephalic regions of the rat. Brain Res. 887 (2000) 421-425
68. 2 receptors for dopamine in human striatum. Neuroreport 12 (2001) 1831-1834
69. Diaz-Cabiale Z., Narvaez J.A., Garcia-Coronel M., and Fuxe K. Galanin/alpha2-adrenoceptor interactions in telencephalic and diencephalic regions of the rat. Neuroreport 12 (2001) 151-155
70. Diaz-Cabiale Z., Vivo M., Del Arco A., O'Connor W.T., Harte M.K., Muller C.E., Martinez E., Popoli P., Fuxe K., and Ferre S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett. 324 (2002) 154-158
71. Diaz-Cabiale Z., Parrado C., Vela C., Razani H., Covenas R., Fuxe K., and Narvaez J.A. Role of galanin and galanin(1-15) on central cardiovascular control. Neuropeptides 39 (2005) 185-190
72. Diaz-Cabiale Z., Parrado C., Rivera A., de la Calle A., Agnati L., Fuxe K., and Narvaez J.A. Galanin-neuropeptide Y (NPY) interactions in central cardiovascular control: involvement of the NPY Y receptor subtype. Eur. J. Neurosci. 24 (2006) 499-508
73. Diaz-Cabiale Z., Parrado C., Fuxe K., Agnati L., and Narvaez J.A. Receptor-receptor interactions in central cardiovascular regulation. Focus on neuropeptide/alpha(2)-adrenoreceptor interactions in the nucleus tractus solitarius. J. Neural Transm. 114 (2007) 115-125
74. Eblen F., and Graybiel A.M. Highly restricted origin of prefrontal cortical inputs to striosomes in the macaque monkey. J. Neurosci. 15 (1995) 5999-6013
75. Farnebo L.O., and Hamberger B. Drug-induced changes in the release of 3 H-monoamines from field stimulated rat brain slices. Acta Physiol. Scand., Suppl. 371 (1971) 35-44
76. Fattore L., Martellotta M.C., Cossu G., Mascia M.S., and Fratta W. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav. Brain Res. 104 (1999) 141-146
77. 2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321 (1997) 143-147
78. 2 receptors in the neostriatum. Brain Res. 594 (1992) 124-130
79. 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7238-7241
80. Ferre S., O'Connor W.T., Fuxe K., and Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13 (1993) 5402-5406
81. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63 (1994) 765-773
82. 1 receptors. Neuroreport 6 (1994) 73-76
83. 1 receptor-mediated mechanisms. Eur. J. Neurosci. 8 (1996) 1545-1553
84. 1 receptor antagonist binding sites. Neurosci. Lett. 208 (1996) 109-112
85. Ferre S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (1997) 482-487
86. 2 receptors in the rat striatum. Neuropharmacology 38 (1999) 129-140
87. Ferre S., Karcz-Kubicha M., Hope B.T., Popoli P., Burgueno J., Gutierrez M.A., Casado V., Fuxe K., Goldberg S.R., Lluis C., Franco R., and Ciruela F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11940-11945
88. Ferrer B., Asbrock N., Kathuria S., Piomelli D., and Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur. J. Neurosci. 18 (2003) 1607-1614
89. 2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10 (2004) 265-271
90. Ferre S., Agnati L.F., Ciruela F., Lluis C., Woods A.S., Fuxe K., and Franco R. Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module. Brain Res. Rev. 55 (2007) 55-67
91. Ferre S., Ciruela F., Woods A.S., Lluis C., and Franco R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci. 30 (2007) 440-446
92. Ferrer B., Gorriti M.A., Palomino A., Gornemann I., de Diego Y., Bermudez-Silva F.J., Bilbao A., Fernandez-Espejo E., Moratalla R., Navarro M., and Rodriguez de Fonseca F. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. Eur. J. Pharmacol. 559 (2007) 180-183
93. 2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 1077 (2006) 67-80
94. Franco R., Ferre S., Agnati L., Torvinen M., Gines S., Hillion J., Casado V., Lledo P., Zoli M., Lluis C., and Fuxe K. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 23 (2000) S50-S59
95. Franco R., Casado V., Mallol J., Ferre S., Fuxe K., Cortes A., Ciruela F., Lluis C., and Canela E.I. Dimer-based model for heptaspanning membrane receptors. Trends Biochem. Sci. 30 (2005) 360-366
96. 1 receptors and accessory proteins. J. Neural Transm. 114 (2007) 93-104
97. French E.D. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226 (1997) 159-162
98. Fuxe K. Biological and pharmacological theories.discussion. In: Bobon D.P., Janssen P.A.J., and Bobon J. (Eds). The Neuroleptics (1970), S. Karger, Basel 121-122 Vol.
99. Fuxe K. Dopamine receptor agonists in brain research and as therapeutic agents. Trends Neurosci. 2 (1979) 1-4
100. Fuxe K., and Agnati L.F. Receptor-receptor Interactions. A New Intramembrane Integrative Mechanism (1987), McMillan Press, London Vol.
101. Fuxe K., and Agnati L. Volume Transmission in the Brain (1991), Raven Press, New York Vol.
102. Fuxe K., Ogren S.O., Agnati L., Gustafsson J.A., and Jonsson G. On the mechanism of action of antidepressant drugs amitryptiline and nortryptiline. Evidence for 5-HT receptor blocking activity. Neurosci. Lett. 6 (1977) 339-343
103. Fuxe K., Agnati L.F., Benfenati F., Cimmino M., Algeri S., Hokfelt T., and Mutt V. Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol. Scand. 113 (1981) 567-569
104. Fuxe K., Agnati L.F., Benfenati F., Celani M., Zini I., Zoli M., and Mutt V. Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J. Neural Transm., Suppl. 18 (1983) 165-179
105. Fuxe K., Celani M.F., Martire M., Zini I., Zoli M., and Agnati L.F. l-glutamate reduces the affinity of [3H]N-propylnorapomorphine binding sites in striatal membranes. Eur. J. Pharmacol. 100 (1984) 127-130
106. Fuxe K., Ogren S.O., Jansson A., Cintra A., Harfstrand A., and Agnati L.F. Intraventricular injections of galanin reduces 5-HT metabolism in the ventral limbic cortex, the hippocampal formation and the fronto-parietal cortex of the male rat. Acta Physiol. Scand. 133 (1988) 579-581
107. Fuxe K., von Euler G., Agnati L.F., and Ogren S.O. Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci. Lett. 85 (1988) 163-167
108. Fuxe K., Agnati L.F., von Euler G., Lundgren K., Zoli M., Bjelke B., Eneroth P., and Ogren S.O. Galanin/5-HT receptor interactions. A new integrative mechanism in the control of 5-HT neurontransmission in the CNS. In: Paoletti R., and Vanhoutte P.M. (Eds). Serotonin from Cell Biology to Pharmacology and Therapeutics (1990), Kluwer Academic Publ. B.V. Dordrecht, The Netherlands 169-185 Vol.
109. Fuxe K., Hedlund P., von Euler G., Lundgren K., Martire M., Ogren S.O., Eneroth P., and Agnati L.F. Galanin/5-HT interactions in the rat centrral nervous system. Relevance for depression. In: Hokfelt T., Bartfai T., Jacobowitz D.M., and Ottoson D. (Eds). Galanin. A New Multifunctional Peptide in the Neuroendocrine System. Wenner-Gren International Series, Vol. 58 (1991), MacMillan Press, London 221-235
110. 2 receptor interactions as a basis for adenosine/dopamine interactionns in the central nervous system. Drug Dev. Res. 28 (1993) 374-380
111. Fuxe K., Li X.M., Bjelke B., Hedlund P.B., Biagini G., and Agnati L.F. Possible mechanisms for the powerful actions of neuropeptides. Ann. N. Y. Acad. Sci. 739 (1994) 42-59
112. Fuxe K., Li X.M., Tanganelli S., Hedlund P., O'Connor W.T., Ferraro L., Ungerstedt U., and Agnati L.F. Receptor-receptor interactions and their relevance for receptor diversity. Focus on neuropeptide/dopamine interactions. Ann. N. Y. Acad. Sci. 757 (1995) 365-376
113. 1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 26 (1998) 258-273
114. Fuxe K., Jansson A., Diaz-Cabiale Z., Andersson A., Tinner B., Finnman U.B., Misane I., Razani H., Wang F.H., Agnati L.F., and Ogren S.O. Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Ann. N. Y. Acad. Sci. 863 (1998) 274-290
115. 2 receptor mediated molecular mechanisms of cannabinoid abuse and cocaine addiction. EU ADDTOMICS.proposal N 004863, LifeSciHealth-I,OJ 2003/C164,FP6-2003. Vol., ed.^eds.
116. 2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61 (2003) S19-S23
117. Fuxe K., Ferre S., Woods A., Rivera A., Hoistad M., Franco R., Kehr J., and Agnati L. Novel strategies for the treatment of Parkinson's Disease. Focus on receptor-receptor interactions in the basal ganglia. In: Kehr J., Fuxe K., Ungerstedt U., and Svensson T. (Eds). Monitoring Molecules in Neuroscience (2003), Karolinska University Press, Stockholm 199-202 Vol.
118. 2 heteromeric receptor complexes and their function. J. Mol. Neurosci. 26 (2005) 209-220
119. Fuxe K., Canals M., Torvinen M., Marcellino D., Terasmaa A., Genedani S., Leo G., Guidolin D., Diaz-Cabiale Z., Rivera A., Lundstrom L., Langel U., Narvaez J., Tanganelli S., Lluis C., Ferre S., Woods A., Franco R., and Agnati L.F. Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J. Neural Transm. 114 (2007) 49-75
120. Fuxe K., Dahlstrom A., Hoistad M., Marcellino D., Jansson A., Rivera A., Diaz-Cabiale Z., Jacobsen K., Tinner-Staines B., Hagman B., Leo G., Staines W., Guidolin D., Kehr J., Genedani S., Belluardo N., and Agnati L.F. From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission. Brain Res. Rev. 55 (2007) 17-54
121. Fuxe K., Ferre S., Genedani S., Franco R., and Agnati L.F. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav. 92 (2007) 210-217
122. Fuxe K., Marcellino D., Genedani S., and Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov. Disord 22 (2007) 1990-2017
123. Fuxe, K., Agnati, L., in press. Cell-cell communication through the extracellular space. In: The New Encyclopedia of Neuroscience. Vol. L.S.e. al., ed.^eds.
124. Gago B., Fuxe K., Agnati L., Penafiel A., De La Calle A., and Rivera A. Dopamine D(4) receptor activation decreases the expression of mu-opioid receptors in the rat striatum. J. Comp. Neurol. 502 (2007) 358-366
125. 2 receptor heterodimers. J. Mol. Neurosci. 26 (2005) 177-184
126. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., and O'Dowd B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275 (2000) 26128-26135
127. George S.R., O'Dowd B.F., and Lee S.P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov. 1 (2002) 808-820
128. Gerdeman G., and Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85 (2001) 468-471
129. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15 (1992) 133-139
130. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15 (1992) 285-320
131. Gilgun-Sherki Y., Melamed E., Mechoulam R., and Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol. Toxicol. 93 (2003) 66-70
132. 1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8606-8611
133. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2 (1999) 358-363
134. 2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17 (1997) 5327-5333
135. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13 (1990) 244-254
136. Greengard P. Possible role for cyclic nucleotides and phosphorylated membrane proteins in postsynaptic actions of neurotransmitters. Nature 260 (1976) 101-108
137. Groenewegen H.J. Organization of the afferent connections of the mediodorsal thalamic nucleus in the rat, related to the mediodorsal-prefrontal topography. Neuroscience 24 (1988) 379-431
138. Hakansson K., Lindskog M., Pozzi L., Usiello A., and Fisone G. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Relat. Disord. 10 (2004) 281-286
139. 2 receptors. J. Neurochem. 96 (2006) 482-488
140. Hashimotodani Y., Ohno-Shosaku T., and Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 13 (2007) 127-137
141. Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
142. Hedlund P., von Euler G., and Fuxe K. Activation of 5-hydroxytryptamine1A receptors increases the affinity of galanin receptors in di- and telencephalic areas of the rat. Brain Res. 560 (1991) 251-259
143. Hedlund P.B., Aguirre J.A., Narvaez J.A., and Fuxe K. Centrally coinjected galanin and a 5-HT1A agonist act synergistically to produce vasodepressor responses in the rat. Eur. J. Pharmacol. 204 (1991) 87-95
144. Hedlund P.B., Yanaihara N., and Fuxe K. Evidence for specific N-terminal galanin fragment binding sites in the rat brain. Eur. J. Pharmacol. 224 (1992) 203-205
145. Hedlund P.B., Finnman U.B., Yanaihara N., and Fuxe K. Galanin-(1-15), but not galanin-(1-29), modulates 5-HT1A receptors in the dorsal hippocampus of the rat brain: possible existence of galanin receptor subtypes. Brain Res. 634 (1994) 163-167
146. Hedlund P.B., and Fuxe K. Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Ann. N. Y. Acad. Sci. 780 (1996) 193-212
147. Hermann H., Marsicano G., and Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109 (2002) 451-460
148. 2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J. Neurosci. 20 (2000) 8987-8995
149. 2 receptors. J. Biol. Chem. 277 (2002) 18091-18097
150. 1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action. J. Cell. Physiol. 191 (2002) 17-27
151. Hurley M.J., Mash D.C., and Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm. 110 (2003) 1279-1288
152. Jackson S.N., Wang H.Y., Yergey A., and Woods A.S. Phosphate stabilization of intermolecular interactions. J. Proteome Res. 5 (2006) 122-126
153. Jansson A., Tinner B., Andbjer B., Razani H., Wang F., Schott P.A., Agnati L.F., Ogren S.O., and Fuxe K. Internalization of intracerebrally administered porcine galanin (1-29) by a discrete nerve cell population in the hippocampus of the rat. Exp. Neurol. 161 (2000) 153-166
154. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 14 (2005) 729-738
155. Jimenez-Vasquez P.A., Diaz-Cabiale Z., Caberlotto L., Bellido I., Overstreet D., Fuxe K., and Mathe A.A. Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders sensitive line rat model of depression. Eur. Neuropsychopharmacol. 17 (2007) 298-308
156. Jonsson G., and Fuxe K. Effects of tetrahydrocannabinols on central monoamine neurons. Acta Pharmacol. Toxicol. (Copenh) 31 (1972)
157. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 (1999) 697-700
158. Joyce J.N., and Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 10 (2005) 917-925
159. Julian M.D., Martin A.B., Cuellar B., Rodriguez De Fonseca F., Navarro M., Moratalla R., and Garcia-Segura L.M. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119 (2003) 309-318
160. Kachroo A., Orlando L.R., Grandy D.K., Chen J.F., Young A.B., and Schwarzschild M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and Parkinsonian mice. J. Neurosci. 25 (2005) 10414-10419
161. Kawaguchi Y., Wilson C.J., and Emson P.C. Intracellular recording of identified neostriatal patch and matrix spiny cells in a slice preparation preserving cortical inputs. J. Neurophysiol. 62 (1989) 1052-1068
162. Kawaguchi Y., Wilson C.J., and Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10 (1990) 3421-3438
163. 2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol. Pharmacol. 67 (2005) 1697-1704
164. Kehr J., Yoshitake T., Wang F.H., Razani H., Gimenez-Llort L., Jansson A., Yamaguchi M., and Ogren S.O. Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology 27 (2002) 341-356
165. Knapp C.M., Foye M.M., Cottam N., Ciraulo D.A., and Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 68 (2001) 797-803
166. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev., Mol. Cell Biol. 6 (2005) 827-837
167. 2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem. Pharmacol. 58 (1999) 1035-1045
168. Kuteeva E., Wardi T., Hokfelt T., and Ogren S.O. Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat. Eur. Neuropsychopharmacol. 17 (2007) 64-69
169. Lange K.W., Rausch W.D., Gsell W., Naumann M., Oestreicher E., and Riederer P. Neuroprotection by dopamine agonists. J. Neural Transm., Suppl. 43 (1994) 183-201
170. Lastres-Becker I., Cebeira M., de Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., and Fernandez-Ruiz J.J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14 (2001) 1827-1832
171. Le Foll B., Frances H., Diaz J., Schwartz J.C., and Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 15 (2002) 2016-2026
172. Le Foll B., Diaz J., and Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47 (2003) 176-183
173. 1 receptor. Cell 111 (2002) 219-230
174. 2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 279 (2004) 35671-35678
175. Lefkowitz R.J., Rajagopal K., and Whalen E.J. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol. Cell 24 (2006) 643-652
176. Levesque M., and Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11888-11893
177. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkotter J., and Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 94 (2007) 29-36
178. 2 receptor mRNA levels in the rat substantia nigra. Brain Res. 679 (1995) 157-167
179. Limbird L.E., Meyts P.D., and Lefkowitz R.J. Beta-adrenergic receptors: evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 64 (1975) 1160-1168
180. Limbird L.E., and Lefkowitz R.J. Negative cooperativity among beta-adrenergic receptors in frog erythrocyte membranes. J. Biol. Chem. 251 (1976) 5007-5014
181. Liu F., Wan Q., Pristupa Z.B., Yu X.M., Wang Y.T., and Niznik H.B. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 403 (2000) 274-280
182. Liu X.Y., Chu X.P., Mao L.M., Wang M., Lan H.X., Li M.H., Zhang G.C., Parelkar N.K., Fibuch E.E., Haines M., Neve K.A., Liu F., Xiong Z.G., and Wang J.Q. Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52 (2006) 897-909
183. Lowther S., De Paermentier F., Cheetham S.C., Crompton M.R., Katona C.L., and Horton R.W. 5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. J. Affect. Disord. 42 (1997) 199-207
184. Lu X., Barr A.M., Kinney J.W., Sanna P., Conti B., Behrens M.M., and Bartfai T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 874-879
185. Manger P.R., Fuxe K., Ridgway S.H., and Siegel J.M. The distribution and morphological characteristics of catecholaminergic cells in the diencephalon and midbrain of the bottlenose dolphin (Tursiops truncatus). Brain Behav. Evol. 64 (2004) 42-60
186. Marcellino D., Roberts D.C., Navarro G., Filip M., Agnati L., Lluis C., Franco R., and Fuxe K. Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal. Brain Res. 1143 (2007) 208-220
187. 2 heteromers. A combined neurochemical and behavioural analysis. Neuropharmacology.
188. 3 receptor interactions in the striatum. J. Biol. Chem.
189. Marshall F.H., White J., Main M., Green A., and Wise A. GABA(B) receptors function as heterodimers. Biochem. Soc. Trans. 27 (1999) 530-535
190. Marshall F.H. Heterodimerization of G-protein-coupled receptors in the CNS. Curr. Opin. Pharmacol. 1 (2001) 40-44
191. Martire M., Fuxe K., Agnati L.F., Pistritto G., and Preziosi P. Galanin increases potassium evoked release of [3H]5-hydroxytryptamine from rat hypothalamic synaptosomal preparations. Neurosci. Lett. 122 (1991) 87-90
192. Mattson B.J., Bossert J.M., Simmons D.E., Nozaki N., Nagarkar D., Kreuter J.D., and Hope B.T. Cocaine-induced CREB phosphorylation in nucleus accumbens of cocaine-sensitized rats is enabled by enhanced activation of extracellular signal-related kinase, but not protein kinase A. J. Neurochem. 95 (2005) 1481-1494
193. Mazarati A.M., Baldwin R.A., Shinmei S., and Sankar R. In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures. J. Neurochem. 95 (2005) 1495-1503
194. Melander T., Hokfelt T., Rokaeus A., Cuello A.C., Oertel W.H., Verhofstad A., and Goldstein M. Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J. Neurosci. 6 (1986) 3640-3654
195. Mihara T., Mihara K., Yarimizu J., Mitani Y., Matsuda R., Yamamoto H., Aoki S., Akahane A., Iwashita A., and Matsuoka N. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J. Pharmacol. Exp. Ther. 323 (2007) 708-719
196. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66 (2004) 1-7
197. Milligan G. G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim. Biophys. Acta 1768 (2007) 825-835
198. Misane I., Razani H., Wang F.H., Jansson A., Fuxe K., and Ogren S.O. Intraventricular galanin modulates a 5-HT1A receptor-mediated behavioural response in the rat. Eur. J. Neurosci. 10 (1998) 1230-1240
199. Morelli M., and Wardas J. Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox. Res. 3 (2001) 545-556
200. Morgan D., Brebner K., Lynch W.J., and Roberts D.C. Increases in the reinforcing efficacy of cocaine after particular histories of reinforcement. Behav. Pharmacol. 13 (2002) 389-396
201. Nakata H., Yoshioka K., Kamiya T., Tsuga H., and Oyanagi K. Functions of heteromeric association between adenosine and P2Y receptors. J. Mol. Neurosci. 26 (2005) 233-238
202. Neisewander J.L., Fuchs R.A., Tran-Nguyen L.T., Weber S.M., Coffey G.P., and Joyce J.N. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 29 (2004) 1479-1487
203. Nishi A., Liu F., Matsuyama S., Hamada M., Higashi H., Nairn A.C., and Greengard P. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1322-1327
204. O'Donnell D., Ahmad S., Wahlestedt C., and Walker P. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J. Comp. Neurol. 409 (1999) 469-481
205. Ogren S.O., Fuxe K., Agnati L.F., Gustafsson J.A., Jonsson G., and Holm A.C. Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugs. J. Neural Transm. 46 (1979) 85-103
206. 2 receptors. Neuroscience 61 (1994) 269-283
207. Olson L., Seiger A., and Fuxe K. Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. Brain Res. 44 (1972) 283-288
208. Parker L.A., Burton P., Sorge R.E., Yakiwchuk C., and Mechoulam R. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 175 (2004) 360-366
209. Parrado C., Diaz-Cabiale Z., Garcia-Coronel M., Agnati L.F., Covenas R., Fuxe K., and Narvaez J.A. Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption. Neuropharmacology 52 (2007) 684-692
210. Petitet F., Jeantaud B., Reibaud M., Imperato A., and Dubroeucq M.C. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63 (1998) PL1-PL6
211. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., and MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
212. 2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J. Comp. Neurol. 495 (2006) 299-313
213. Pieribone V.A., Xu Z.Q., Zhang X., Grillner S., Bartfai T., and Hokfelt T. Galanin induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the brainstem slice. Neuroscience 64 (1995) 861-874
214. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev., Neurosci. 4 (2003) 873-884
215. Pistis M., Porcu G., Melis M., Diana M., and Gessa G.L. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur. J. Neurosci. 14 (2001) 96-102
216. Popken G.J., Bunney Jr. W.E., Potkin S.G., and Jones E.G. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9276-9280
217. Popoli P., Betto P., Reggio R., and Ricciarello G. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287 (1995) 215-217
218. 1 receptors prevents the EEG arousal due to dopamine D1 receptor activation in rabbits. Eur. J. Pharmacol. 305 (1996) 123-126
219. 1 receptor stimulation in rodents. Neurosci. Lett. 218 (1996) 209-213
220. Popoli P., Pezzola A., Torvinen M., Reggio R., Pintor A., Scarchilli L., Fuxe K., and Ferre S. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25 (2001) 505-513
221. Prinster S.C., Hague C., and Hall R.A. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57 (2005) 289-298
222. Quarta D., Ciruela F., Patkar K., Borycz J., Solinas M., Lluis C., Franco R., Wise R.A., Goldberg S.R., Hope B.T., Woods A.S., and Ferre S. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology 32 (2007) 35-42
223. 2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 654-659
224. Razani B., Woodman S.E., and Lisanti M.P. Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54 (2002) 431-467
225. Razani H., Diaz-Cabiale Z., Fuxe K., and Ogren S.O. Intraventricular galanin produces a time-dependent modulation of 5-HT1A receptors in the dorsal raphe of the rat. Neuroreport 11 (2000) 3943-3948
226. Razani H., Diaz-Cabiale Z., Misane I., Wang F.H., Fuxe K., and Ogren S.O. Prolonged effects of intraventricular galanin on a 5-hydroxytryptamine(1A) receptor mediated function in the rat. Neurosci. Lett. 299 (2001) 145-149
227. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X., el Mestikawy S., Hamon M., and Descarries L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol. 417 (2000) 181-194
228. Rimondini R., Ferre S., Ogren S.O., and Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17 (1997) 82-91
229. Rimondini R., Ferre S., Gimenez-Llort L., Ogren S.O., and Fuxe K. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur. J. Pharmacol. 347 (1998) 153-158
230. Rivera A., Cuellar B., Giron F.J., Grandy D.K., de la Calle A., and Moratalla R. Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J. Neurochem. 80 (2002) 219-229
231. Rivera A., Trias S., Penafiel A., Angel Narvaez J., Diaz-Cabiale Z., Moratalla R., and de la Calle A. Expression of D4 dopamine receptors in striatonigral and striatopallidal neurons in the rat striatum. Brain Res. 989 (2003) 35-41
232. Rodriguez J.J., Mackie K., and Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J. Neurosci. 21 (2001) 823-833
233. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
234. 2 receptor-induced responses in stably transfected human neuroblastoma cells. J. Neurochem. 74 (2000) 432-439
235. 3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276 (2001) 30308-30314
236. Schiffmann S.N., and Vanderhaeghen J.J. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13 (1993) 1080-1087
237. 3 receptor coexistence. Brain Res. Brain Res. Rev. 26 (1998) 236-242
238. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.F., and Morelli M. Targeting adenosine A(2A) receptors in Parkinson's disease. Trends Neurosci. 29 (2006) 647-654
239. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1 (1987) 133-152
240. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., and Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse 60 (2006) 319-346
241. 2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine. Mol. Pharmacol. 58 (2000) 455-462
242. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., and Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001) 2108-2111
243. Skofitsch G., and Jacobowitz D.M. Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. Peptides 6 (1985) 509-546
244. Skofitsch G., Sills M.A., and Jacobowitz D.M. Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides 7 (1986) 1029-1042
245. Soria G., Castane A., Ledent C., Parmentier M., Maldonado R., and Valverde O. The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 31 (2006) 978-987
246. Soria G., Mendizabal V., Tourino C., Robledo P., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30 (2005) 1670-1680
247. Staley J.K., and Mash D.C. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 16 (1996) 6100-6106
248. Stansfield K.H., and Kirstein C.L. Effects of novelty on behavior in the adolescent and adult rat. Dev. Psychobiol. 48 (2006) 10-15
249. 2 receptor regulation in the rat dopamine-denervated striatum. Eur. J. Neurosci. 12 (2000) 4033-4037
250. Surmeier D.J., Song W.J., and Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16 (1996) 6579-6591
251. 2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 30 (2007) 228-235
252. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Brain Res. Rev. 31 (2000) 320-329
253. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hokfelt T., Wolinsky T.D., Konkel M.J., Chen H., Zhong H., Walker M.W., Craig D.A., Gerald C.P., and Branchek T.A. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17489-17494
254. Szabo B., Siemes S., and Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neurosci. 15 (2002) 2057-2061
255. 2 interactions in models of Parkinson's Disease. Parkinsonism Relat. Disord. 10 (2004) 273-280
256. Tennyson V.M., Barrett R.E., Cohen G., Cote L., Heikkila R., and Mytilineou C. The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and (3 H)dopamine uptake. Brain Res. 46 (1972) 251-285
257. Terrillon S., and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5 (2004) 30-34
258. Toda S., Alguacil L.F., and Kalivas P.W. Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J. Neurochem. 87 (2003) 1478-1484
259. Torvinen M., Gines S., Hillion J., Latini S., Canals M., Ciruela F., Bordoni F., Staines W., Pedata F., Agnati L.F., Lluis C., Franco R., Ferre S., and Fuxe K. Interactions among adenosine deaminase, adenosine A(1) receptors and dopamine D(1) receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 113 (2002) 709-719
260. Torvinen M., Marcellino D., Canals M., Agnati L.F., Lluis C., Franco R., and Fuxe K. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol. Pharmacol. 67 (2005) 400-407
261. 2 receptors. J. Mol. Neurosci. 25 (2005) 191-200
262. Tran-Nguyen L.T., Fuchs R.A., Coffey G.P., Baker D.A., O'Dell L.E., and Neisewander J.L. Time-dependent changes in cocaine-seeking behavior and extracellular dopamine levels in the amygdala during cocaine withdrawal. Neuropsychopharmacology 19 (1998) 48-59
263. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., and Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 27 (2007) 3663-3676
264. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., Fujiwara Y., Sakai A., and Kuroda S. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 7 (2002) 515-518
265. Vlachou S., Nomikos G.G., and Panagis G. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav. Brain Res. 141 (2003) 215-222
266. Vorel S.R., Ashby Jr. C.R., Paul M., Liu X., Hayes R., Hagan J.J., Middlemiss D.N., Stemp G., and Gardner E.L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 22 (2002) 9595-9603
267. 2 dopamine receptor activation. J. Pharmacol. Exp. Ther. 308 (2004) 221-227
268. 2 dopamine receptor-induced sensitization of adenylyl cyclase type 1 is G alpha(s) independent. Neuropharmacology 50 (2006) 576-584
269. Waters S.M., and Krause J.E. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 95 (2000) 265-271
270. Watts V.J. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J. Pharmacol. Exp. Ther. 302 (2002) 1-7
271. Weerts E.M., and Griffiths R.R. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl) 168 (2003) 155-163
272. Weiss J.M., Bonsall R.W., Demetrikopoulos M.K., Emery M.S., and West C.H. Galanin: a significant role in depression?. Ann. N. Y. Acad. Sci. 863 (1998) 364-382
273. White N.M., and Hiroi N. Preferential localization of self-stimulation sites in striosomes/patches in the rat striatum. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6486-6491
274. Woods A.S., Ciruela F., Fuxe K., Agnati L.F., Lluis C., Franco R., and Ferre S. Role of electrostatic interaction in receptor-receptor heteromerization. J. Mol. Neurosci. 26 (2005) 125-132
275. Wrenn C.C., and Crawley J.N. Pharmacological evidence supporting a role for galanin in cognition and affect. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001) 283-299
276. Wu H.Q., Fuxe K., and Schwarcz R. Neuronal A1 receptors mediate increase in extracellular kynurenic acid after local intrastriatal adenosine infusion. J. Neurochem. 90 (2004) 621-628
277. Xu Z.Q., Zhang X., Pieribone V.A., Grillner S., and Hokfelt T. Galanin-5-hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience 87 (1998) 79-94
278. Yan Z., Feng J., Fienberg A.A., and Greengard P. D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11607-11612
279. Yoshitake T., Reenila I., Ogren S.O., Hokfelt T., and Kehr J. Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci. Lett. 339 (2003) 239-242
280. Zavitsanou K., Garrick T., and Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 355-360
281. Zoli M., Agnati L.F., Hedlund P.B., Li X.M., Ferre S., and Fuxe K. Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol. Neurobiol. 7 (1993) 293-334
282. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., and Guimaraes F.S.
283. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., and Crippa J.A. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 20 (2006) 683-686